United BioPharma (UBP, 6471) has announced that the company received an e official letter of designation from Industrial Development Bureau (IDB), Ministry of Economic Affairs (MOEA) as a technology enterprise. UBP is focused on the development and manufacture of monoclonal therapeutics. Their current pipeline includes five (5) innovative drugs and three (3) biosimilars, among which is their most advanced anti-CD4 mAb UB-421, which has just completed a clinical phase II trial, to evaluate the possibility as a substitution for or in combination with Highly Active Antiretroviral Therapy (HAART) UBP plans to apply for a phase III clinical trial in Taiwan at the end of 2016 and to apply for a multi-national and multi –center (Taiwan, China and US) phase III clinical trial in the first quarter of 2017.. UBP will seek a direct path to CFDA and apply for breakthrough designation to US FDA. UBP is also planning a phase IIb/III clinical trial in the US via an orphan drug designation on patients failing HAART. UBP is also collaborating with NIAID of NIH to explore a functional cure of HIV infection by UB-421.
United Biopharma has an experienced R&D team, multiple high market value products in its pipeline, state-of-the-art R&D and manufacturing facilities. With the Technology Enterprise qualification, a unique qualification on the Taiwan stock market, United BioPharma will submit an Initial Public Offering application to the Taiwan over-the-counter market in the near future.
About United BioPharma (6471)
United BioPharma (UBP) was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnered with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind. For more information, please visit http://www.unitedbiopharma.com
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.
Victor Run-Ben Sun
Spokesperson and Vice President of Public Affairs